ArticleInflammation2026
Obesity-induced Nerve Degeneration and Inflammation: Therapeutic Effects of β-Hydroxybutyrate and Melatonin on Pyroptosis, ER Stress, and Hippocampal Dysfunction in High-Fat Diet-Fed Rats.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Obesity-induced neurodegeneration is mediated by multiple pathological mechanisms, including inflammation, oxidative stress, pyroptosis, and endoplasmic reticulum (ER) stress, with pyroptosis and ER stress emerging as central contributors. This study investigated the neuroprotective efficacy of β-hydroxybutyrate (BHB) and melatonin, both individually and in combination, in mitigating these pathways and attenuating obesity-associated neurodegeneration. Thirty male Sprague-Dawley rats were allocated into five groups over a 7-week experimental period: (1) Control (standard diet); (2) High-fat diet (HFD), administered daily via oral gavage as an emulsion; (3) HFD + BHB (4% in drinking water); (4) HFD + melatonin (10 mg/kg/day in drinking water); and (5) HFD + BHB + melatonin. Post-treatment, blood and brain tissues were analyzed for biochemical markers, histopathological changes, and mRNA expression levels of pyroptosis-related (NLRP3, Caspase-1, Caspase-3, Caspase-11, GSDMD, NF-κB, IL-1β, IL-10) and ER stress-related (BIP, CHOP, sXBP1, TXNIP) genes via quantitative RT-PCR. Co-administration of BHB and melatonin significantly elevated serum ketone levels, ameliorated HFD-induced dyslipidemia, and attenuated weight gain (p < 0.001). Histopathological analysis revealed preserved neuronal density, volume, and architecture in the hippocampal CA1 and dentate gyrus (DG) regions, alongside reduced neurodegeneration (p < 0.001). The combined intervention suppressed neuroinflammatory markers and oxidative stress while elevating anti-inflammatory IL-10 levels. Furthermore, it downregulated pyroptosis-related (NLRP3, Caspase-1, Caspase-3, Caspase-11, GSDMD, NF-κB, IL-1β) and ER stress-related (BiP, CHOP, sXBP1, TXNIP) gene expressions (p < 0.001), suggesting a dual mechanism of action. BHB and melatonin demonstrate significant potential in counteracting obesity-driven neurodegeneration through synergistic anti-inflammatory, anti-pyroptotic, and ER stress-modulating effects. Their combined administration presents a multi-targeted therapeutic strategy to preserve neuronal integrity and mitigate brain damage in obesity. These findings corroborate prior evidence and underscore the translational relevance of BHB and melatonin in managing obesity-related neural pathologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.